Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection
Brief Summary: This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV) administered for 8 or 12 weeks in treatment-naive participants with chronic genotype 1 HCV infection.


Options:
A: Arm Label: ABT-450/r/ABT-267 and ABT-333, plus RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin | Arm Label: Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin, Drug: Placebo for ABT-450/r/ABT-267, Drug: Placebo for ABT-333, Drug: Placebo for ribavirin | Intervention Type: DRUG; Name: ABT-450/r/ABT-267, ABT-333; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, plus RBV, Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, plus RBV, Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV | Intervention Type: DRUG; Name: Placebo for ABT-450/r/ABT-267; Assigned to Arm(s): Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV | Intervention Type: DRUG; Name: Placebo for ABT-333; Assigned to Arm(s): Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV | Intervention Type: DRUG; Name: Placebo for ribavirin; Assigned to Arm(s): Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV
B: Arm Label: LDV/SOF 8 Week; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV 8 Week; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: LDV/SOF 12 Week; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Intervention Type: DRUG; Name: LDV/SOF; Assigned to Arm(s): LDV/SOF 12 Week, LDV/SOF 8 Week, LDV/SOF+RBV 8 Week | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): LDV/SOF+RBV 8 Week
C: Arm Label: BI201335 12W; Type: EXPERIMENTAL; Interventions: Drug: PegIFN/RBV, Drug: BI201335 | Arm Label: BI 201335 24W; Type: EXPERIMENTAL; Interventions: Drug: BI201335 24W, Drug: PegIFN/RBV | Arm Label: BI 201335 24 W; Type: EXPERIMENTAL; Interventions: Drug: PegIFN/RBV, Drug: Bi 201335 | Intervention Type: DRUG; Name: PegIFN/RBV; Assigned to Arm(s): BI 201335 24 W | Intervention Type: DRUG; Name: PegIFN/RBV; Assigned to Arm(s): BI201335 12W | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): BI201335 12W | Intervention Type: DRUG; Name: BI201335 24W; Assigned to Arm(s): BI 201335 24W | Intervention Type: DRUG; Name: PegIFN/RBV; Assigned to Arm(s): BI 201335 24W | Intervention Type: DRUG; Name: Bi 201335; Assigned to Arm(s): BI 201335 24 W
D: Arm Label: Arm 1: Null or Partial Responder to P/R (ASV + DCV); Type: EXPERIMENTAL; Interventions: Drug: Asunaprevir (ASV), Drug: Daclatasvir (DCV) | Arm Label: Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV); Type: EXPERIMENTAL; Interventions: Drug: Asunaprevir (ASV), Drug: Daclatasvir (DCV) | Arm Label: Arm 3: Treatment naive (ASV + DCV); Type: EXPERIMENTAL; Interventions: Drug: Asunaprevir (ASV), Drug: Daclatasvir (DCV), Drug: Pegylated-interferon alfa 2a (PegIFN), Drug: Ribavirin (RBV) | Arm Label: Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week; Type: EXPERIMENTAL; Interventions: Drug: Asunaprevir (ASV), Drug: Daclatasvir (DCV), Drug: Pegylated-interferon alfa 2a (PegIFN), Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: Asunaprevir (ASV); Assigned to Arm(s): Arm 1: Null or Partial Responder to P/R (ASV + DCV), Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV), Arm 3: Treatment naive (ASV + DCV), Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week | Intervention Type: DRUG; Name: Daclatasvir (DCV); Assigned to Arm(s): Arm 1: Null or Partial Responder to P/R (ASV + DCV), Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV), Arm 3: Treatment naive (ASV + DCV), Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week | Intervention Type: DRUG; Name: Pegylated-interferon alfa 2a (PegIFN); Assigned to Arm(s): Arm 3: Treatment naive (ASV + DCV), Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): Arm 3: Treatment naive (ASV + DCV), Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week

Answer: B